Obesity
Conditions
Brief summary
The TOGA® trial is a prospective, multi-center, randomized sham-controlled trial designed to determine the safety and effectiveness of the TOGA System for the treatment of morbid obesity. The study will also determine the effect of the treatment on co-morbidities and quality of life. Subjects will be blinded to treatment or sham. Sham arm may crossover to TOGA treatment at 12 months.
Interventions
DEVICETOGA
Transoral Gastroplasty (TOGA®) System for gastric stapling.
DEVICEControl
The control device (bougie dilator) is a FDA-cleared (Class II) device.
Sponsors
Satiety, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-60 2. BMI ≥ 40 kg/m2 and \< 55 kg/m2, or BMI ≥ 35 kg/m2 with one or more significant co morbidities 3. History of obesity for at least 2.5 years. 4. History of stable weight (defined as a \< 10% change in excess weight) for one year prior to the screening visit. 5. History of failure with non-surgical weight loss methods. 6. Suitable candidate for bariatric surgery based on the results of their psychological and physical evaluations. 7. Understands risks of procedure, agrees to follow protocol requirements, including signing informed consent, returning for follow-up visits, completing all required testing, completing diet and behavior modification counseling, committing to prolonged lifestyle changes, and agrees to comply with the substantial dietary restrictions required by the procedure. 8. Subject lives, and intends to remain, within a 100 mile radius of the study center for 5 years.
Exclusion criteria
1. Hormonal or genetic cause for the obese state. 2. History of cancer other than localized basal cell carcinoma. 3. History of inflammatory disease of the gastrointestinal tract including Crohn's disease, ulcerative colitis, severe intractable esophagitis, gastric ulceration, or esophageal or duodenal ulceration. 4. Active peptic ulcer disease. 5. Significant known esophageal disease, including Zenker's diverticulum, grade 3-4 reflux esophagitis, stricture, Barrett's esophagus, esophageal cancer, esophageal diverticulum, dysphagia, achalasia, diffuse esophageal spasm, and symptoms of dysmotility. 6. Myocardial infarction or cerebrovascular accident within past year. 7. Angina pectoris. 8. Inability to extend neck or fully open mouth. 9. Clinically severe cervical spinal disease, including cervical disc disease, vertebral osteophytes. 10. Critically loose teeth. 11. Temporomandibular joint syndrome (TMJ) or patients at risk for developing TMJ. 12. Severe coagulopathy (prothrombin time \> 3 seconds over control or platelet count \< 100,000) 13. Gastroparesis 14. Upper GI bleeding conditions such as esophageal or gastric varices, portal hypertensive gastropathy, congenital or acquired intestinal telangiectasis. 15. Congenital or acquired anomalies of the GI tract such as atresias or stenoses. 16. Structural abnormalities of the GI tract such as diverticulum. 17. Lesions with increased risk of bleeding. 18. Hiatal hernia ≥ 2cm. 19. Severe cardiopulmonary disease or other serious organic disease, including HIV or cancer. 20. Congestive heart failure. 21. Uncontrolled hypertension (systolic \>150 or diastolic \> 100). 22. Advanced rheumatoid arthritis. 23. Severe or advanced liver disease (such as cirrhosis, chronic hepatitis, portal hypertension, etc.). 24. Chronic pancreatitis. 25. Any contraindication to endoscopy. 26. Severe reflux disease. 27. Currently pregnant or nursing. 28. Potentially childbearing (i.e. not post-menopausal or surgically sterilized) and not willing to use an effective method of contraception for the next 24 months. 29. Alcohol (\> 80 gm/day of ethanol) or illicit drug use within the last 3 years. 30. Prior gastric, esophageal, pancreatic or bariatric surgery. 31. Currently on prescription or over the counter diet drugs. 32. Chronic therapy with aspirin, NSAID or anticoagulants. 33. Systemic infection at the time of the procedure. 34. Patient with a known diagnosis or pre-existing symptoms of autoimmune connective tissue disease (i.e., systemic lupus erythematosus or scleroderma). 35. Thyroid disease which is not controlled with medication 36. Unacceptable medical risk (general health status would preclude surgery should a complication occur). 37. Not ambulatory. 38. Participating in another ongoing clinical trial in which concomitant diagnosis or therapeutic intervention would adversely affect the integrity of the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness: The proportion of subjects with ≥ 25% EWL (excess weight loss); Safety: Pre-defined objective performance criteria (OPC) | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in Co-morbidities; Improvements in other Obesity Measures and in Quality of Life Measures | 12 months |
Countries
Belgium, United States
Outcome results
None listed